Biologically Active Small Molecules

A non-nucleoside inhibitor of the RNA-directed RNA polymerase of HCV.

A non-nucleoside inhibitor of the RNA-directed RNA polymerase of HCV.

BH3 mimetic and inhibitor of Bcl-2, Bcl-xl, and Bcl-w. It inhibits growth of acute myelogenous leukemia cells and induces apoptosis and clearance in platelets.

BH3 mimetic and inhibitor of Bcl-2, Bcl-xl, and Bcl-w. It inhibits growth of acute myelogenous leukemia cells and induces apoptosis and clearance in platelets.

A potent, cell-permeable mimetic of BH3 domains that avidly binds Bcl-2, Bcl-xL, and Bcl-W (Ki death proteins, leading to apoptosis.

A potent, cell-permeable mimetic of BH3 domains that avidly binds Bcl-2, Bcl-xL, and Bcl-W (Ki death proteins, leading to apoptosis.

A potent, cell-permeable mimetic of BH3 domains that avidly binds Bcl-2, Bcl-xL, and Bcl-W (Ki death proteins, leading to apoptosis.

A potent, cell-permeable mimetic of BH3 domains that avidly binds Bcl-2, Bcl-xL, and Bcl-W (Ki death proteins, leading to apoptosis.

An ATP-competitive, multi-targeted RTK inhibitor that inhibits all members of the VEGF and PDGF receptor families (IC₅₀s = 4-190 nM) inhibits proliferation in MV-4-11 and MOLM-13 cells (IC₅₀s = 4 and 6 nM, respectively).

An ATP-competitive, multi-targeted RTK inhibitor that inhibits all members of the VEGF and PDGF receptor families (IC₅₀s = 4-190 nM) inhibits proliferation in MV-4-11 and MOLM-13 cells (IC₅₀s = 4 and 6 nM, respectively).

An ATP-competitive, multi-targeted RTK inhibitor that inhibits all members of the VEGF and PDGF receptor families (IC₅₀s = 4-190 nM) inhibits proliferation in MV-4-11 and MOLM-13 cells (IC₅₀s = 4 and 6 nM, respectively).

An orally bioavailable inhibitor of PARP1 and PARP2 (Kis = 5.2 and 2.9 nM, respectively) enhances apoptosis and autophagy in response to treatments that cause DNA breaks, including radiation and DNA alkylation.